Journals / Türk Hijyen ve Deneysel Biyoloji Dergisi / 2022 / Cilt: 79 - Sayı: 1

The role of molecular mechanisms in targeted therapy strategies in ovarian cancer

Yumurtalık kanserinde hedefe yönelik tedavi stratejilerinde moleküler mekanizmaların rolü

Pages
153–162
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It will be possible to increase the quality of the healing process of patients suffering from this disease by enlightening the molecular characterizations of the treatment methods that are available and still being developed in the treatment of ovarian cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cancer is a disease that occurs in tissues and organs as a result of uncontrolled cell divisions.
📊
Key Findings & Data:There are numerous types of cancer related with different frequencies and mortality rate.
💡
Conclusion & Impact:It will be possible to increase the quality of the healing process of patients suffering from this disease by enlightening the molecular characterizations of the treatment methods that are available and still being developed in the treatment of ovarian cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cancer is a disease that occurs in tissues and organs as a result of uncontrolled cell divisions. There are numerous types of cancer related with different frequencies and mortality rate. Ovarian cancer is the seventh common type of cancer worldwide and is the fifth cause of cancer-related death. Although there are standard treatment methods for cancer types, people give different responses to these treatment methods. In spite of all the treatment strategy developed, ovarian cancer still has a high mortality rate. For this reason, it is very important to better understand the drug resistance mechanisms that prevent the effecttiveness of today’s treatment methods, to develop new treatment methods and the determination of molecular characterization. In recent years, research has focused on methods containing pathway analysis within the scope of developing targeted therapy strategies for ovarian cancer. In this context, the activity status of onco-proteins in pathways such as WNT, Hedgehog and NOTCH signaling pathways were evaluated. In addition, the innovative treatment efficiency of Nanog protein and photodynamic therapy options on ovarian cancer has been detailed in recent years. It will be possible to increase the quality of the healing process of patients suffering from this disease by enlightening the molecular characterizations of the treatment methods that are available and still being developed in the treatment of ovarian cancer.

Özet

Kanser, kontrol edilemeyen hücre bölünmeleri sonucunda doku ve organlarda meydana gelen hasarların bütünüdür. Farklı görülme sıklığı ve ölüm oranları ile ilişkili birçok kanser türü vardır. Yumurtalık kanseri dünya genelinde yaygınlık olarak yedinci sırada gelmekte olup kansere bağlı ölüm nedeni olarak beşinci sırada gelmektedir. Kanser türlerinin kendi içinde standart tedavi yöntemleri olmasına rağmen bireyler bu tedavi yöntemlerine farklı cevaplar vermektedir. Geliştirilen tüm tedavi stratejilerine rağmen yumurtalık kanseri hala yüksek ölüm oranına sahiptir. Bu sebeple günümüzdeki tedavi yöntemlerinin etkinliğini engelleyen ilaca karşı oluşan direnç mekanizmalarını kavramak, yeni tedavi yöntemleri geliştirmek ve moleküler karakterizasyonunu belirlemek oldukça önemlidir. Son yıllarda oldukça gündeme gelen yumurtalık kanserinde hedefe yönelik terapi stratejileri geliştirilmesi kapsamında yolak analizleri üzerine odaklanılmıştır. Bu kapsamda onko- proteinlerin WNT, Hedgehog ve NOTCH sinyal yolağı gibi yolaklardaki etkinlik durumları değerlendirilmiştir. Ayrıca, son yıllarda etkinliği belirlenmiş Nanog proteini ve fotodinamik tedavi seçeneklerinin yumurtalık kanseri üzerindeki yenilikçi tedavi etkinliği detaylandırılmıştır. Yumurtalık kanseri tedavisinde mevcut ve geliştirilmesihâlâ devam eden tedavi yöntemlerinin moleküler karakterizasyonlarının aydınlatılması ile bu hastalıktan şikayeti olan hastaların iyileşme süreçlerinin kalitesinin artırılması mümkün hâle gelebilecektir.

🔖

Cite This Article

ÇOLAK, B., DUMAN, D. C., YILMAZ, E. (2022). The role of molecular mechanisms in targeted therapy strategies in ovarian cancer. Türk Hijyen ve Deneysel Biyoloji Dergisi, Cilt: 79 - Sayı: 1, 153–162. https://ajindex.com/articles/624883

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Roy PS, Saikia BJ. Cancer and cure: a critical analysis. Indian J Cancer, 2016; 53 (3): 441-2
  2. Torre LA, Siegel RG, Ward EM, Jemal A. global cancer incidence and mortality rates and trends- -an update. Cancer Epidemiol Biomarkers Prev, 2016; 25 (1): 16-27
  3. Ottevanger, PB. Ovarian cancer stem cells more questions than answers. Semin Cancer Biol, 2017; 44: 67-71
  4. Keyvani V, Farshchian M, Esmaeili SA, Yari H, Moghbeli M, Nezhad SRK, et al. Ovarian cancer stem cells and targeted therapy. J Ovarian Res, 2019; 12 (1): 120
  5. Türkiye Kanser İstatistikleri, 2010. https:// hsgm.saglik.gov.tr/tr/kanser-istatistikleri/ yillar/2010-yili-kanser istatistikleri.html, (Erişim Tarihi: 23.02.2020)
  6. Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer, 2003; 97 (10): 2631-42
  7. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer. Cancer Biol Med, 2017; 14 (1):9-32
  8. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol, 2006; 20 (2): 207-25
  9. Reavis HD, Drapkin R. The tubal epigenome an emerging target for ovarian cancer. Pharmacol Therap, 2020; 210: 107524
  10. Koshiyama M, Konishi I, Mandai M, Komatsu T, Yamamoto S, Nanbu K, et al. Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status. Virchows Arch, 1995; 425 (6): 603-9
  11. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer, 2004; 112 (1): 14-25
  12. Salani R, Kurman RJ, Giuntoli R, Gardner G, Bristow R, Wang TL, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer, 2008; 18 (3): 487-91
  13. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol, 2009; 4: 287-313
  14. Koshiyama M, Matsumura N, Konishi I. Subtypes of ovarian cancer and ovarian cancer screening. Diagnostics, 2017; 7 (1): 12
  15. Baykara O. Current modalities in treatment of cancer. Balıkesir Health Sci J, 2016; 5: 154-65
  16. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased plat